NAMS NewAmsterdam Pharma Co N.V.

CIK 0001936258 44 ready 8-Ks latest July 24, 2026, 8:03 AM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 44

Latest filing July 24, 2026, 8:03 AM ET

Top materiality 0.90

Event mix other_material ×24 · earnings ×8 · leadership ×7

Sentiment 16 pos · 3 neg · 25 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for NAMS

Highest-materiality recent filing

NewAmsterdam Pharma Reports Phase 3 BROADWAY and TANDEM Data Published in NEJM and Lancet

May 7, 2025, 7:59 PM ET other material materiality 0.90 positive item 7.01 item 8.01 item 9.01

BROADWAY trial showed 33% LDL-C reduction (p<0.0001) vs placebo and a 21% relative reduction in MACE (HR=0.79).
TANDEM trial fixed-dose combination of obicetrapib and ezetimibe achieved 48.6% LDL-C reduction vs placebo (p<0.001).

Read filing →

July 24, 2026, 8:03 AM ET regulatory materiality 0.75 positive item 8.01 item 9.01

NewAmsterdam Pharma and Menarini receive positive CHMP opinion for obicetrapib products in Europe

CHMP recommends marketing authorization for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib/ezetimibe FDC) for hypercholesterolemia.
May 7, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

NewAmsterdam Pharma reports Q1 net loss of $48.4M; PREVAIL interim analysis planned for 4Q26

Net loss $48.4M for Q1 2026, compared to net loss $39.5M in Q1 2025.
February 18, 2026, 6:59 PM ET other material materiality 0.65 neutral item 2.02 item 9.01

NewAmsterdam Pharma reports $728.9M cash, obicetrapib regulatory decisions expected 2H26

Regulatory decisions from EMA, UK, Switzerland for obicetrapib monotherapy & FDC expected in 2H26.
January 9, 2026, 6:59 PM ET other material materiality 0.65 positive item 2.02 item 7.01 item 9.01

NewAmsterdam provides pipeline update; cash ~$729M; EMA decision expected 2H26

Unaudited cash, cash equivalents and marketable securities ~$729M as of Dec 31, 2025.
November 5, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01

NewAmsterdam Pharma Q3 net loss widens to $72M; EMA accepts MAAs for obicetrapib

Cash, equivalents and securities $756M as of Sep 30, 2025, down from $834.2M at Dec 31, 2024.
August 18, 2025, 7:59 PM ET regulatory materiality 0.70 positive item 7.01 item 8.01 item 9.01

EMA validates MAA for NewAmsterdam's obicetrapib monotherapy and FDC with ezetimibe

EMA will review Phase 3 BROADWAY, BROOKLYN and TANDEM trials supporting obicetrapib 10 mg and obicetrapib/ezetimibe FDC.
August 6, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

NewAmsterdam Q2 net loss narrows to $17.4M; obicetrapib data published in NEJM and Lancet

Cash, equivalents and securities $783.3M at June 30, 2025, down from $834.2M at Dec 31, 2024.
July 30, 2025, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

NewAmsterdam: Obicetrapib significantly reduces p-tau217 in ApoE4 carriers in BROADWAY

p-tau217 reduced in full analysis set (p=0.0019, n=1,515) and ApoE4 carriers (p=0.0215, n=367).
June 9, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

NewAmsterdam reports positive AD biomarker data from BROADWAY; p-tau217 reduced in ITT and ApoE4 carriers

Statistically significant lower absolute change in p-tau217 over 12 months vs placebo in full ITT (p<0.002) and ApoE4 carriers (p=0.0215).
May 8, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

NewAmsterdam Pharma reports Q1 net loss $39.5M; cash $808.5M; EMA submission on track for 2H25

Cash $808.5M at Mar 31, 2025, down from $834.2M at Dec 31, 2024.
May 7, 2025, 7:59 PM ET other material materiality 0.90 positive item 7.01 item 8.01 item 9.01

NewAmsterdam Pharma Reports Phase 3 BROADWAY and TANDEM Data Published in NEJM and Lancet

BROADWAY trial showed 33% LDL-C reduction (p<0.0001) vs placebo and a 21% relative reduction in MACE (HR=0.79).
February 26, 2025, 6:59 PM ET earnings materiality 0.72 neutral item 2.02 item 9.01

NewAmsterdam reports FY2024 net loss $241.6M, cash $834M; EMA submission on track for 2H25

Cash, cash equivalents and marketable securities totaled $834.2M at Dec 31, 2024, up from $340.5M.
January 10, 2025, 6:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

NewAmsterdam provides 2024-2025 update: Phase 3 data, $835M cash, EMA filing in 2H25

BROADWAY Phase 3 met primary endpoint: 33% LS mean LDL-C reduction (p<0.0001); exploratory MACE reduction of 21%.
December 13, 2024, 6:59 PM ET other material materiality 0.75 neutral item 1.01 item 7.01 item 9.01

NewAmsterdam Pharma prices $416.5M upsized public offering; net proceeds ~$452.6M

Pricing of 12,117,347 ordinary shares at $24.50/share and 4,882,653 pre-funded warrants at $24.4999/warrant.
December 10, 2024, 6:59 PM ET other material materiality 0.85 positive item 7.01 item 9.01

NewAmsterdam reports positive Phase 3 BROADWAY topline: 33% LDL-C reduction, 21% MACE reduction

Primary endpoint met: LS mean LDL-C reduction of 33% (p<0.0001) vs placebo at day 84 on top of maximally tolerated therapies.
November 20, 2024, 6:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

NewAmsterdam Pharma reports positive Phase 3 TANDEM topline data; FDC lowers LDL-C 48.6% vs placebo

Fixed-dose combination of obicetrapib 10 mg and ezetimibe 10 mg achieved LS mean LDL-C reduction of 48.6% (p<0.0001) vs placebo at day 84.
November 18, 2024, 6:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

NewAmsterdam Pharma reports Phase 3 BROOKLYN trial: LDL-C reduced 36.3% vs placebo at day 84, Lp(a) reduced 45.9%

LDL-C mean reduction vs placebo 36.3% at day 84 (p<0.0001), sustained at 41.5% at day 365.
November 6, 2024, 6:59 PM ET other material materiality 0.65 positive item 2.02 item 9.01

NewAmsterdam Pharma Q3 net loss $16.6M; Phase 3 TANDEM topline expected Q4 2024

Cash $422.7M as of Sep 30, 2024, up from $340.5M at Dec 31, 2023.
October 18, 2024, 7:59 PM ET other material materiality 0.80 negative item 4.02

NewAmsterdam Pharma to restate 2022 and 2021 financials due to EPS calculation errors

Audit committee concluded 2021 and 2022 financial statements should not be relied upon due to net loss per share errors.
August 7, 2024, 7:59 PM ET earnings materiality 0.90 positive item 2.02 item 9.01

NewAmsterdam reports positive Phase 3 BROOKLYN data; Q2 net loss $39M

Phase 3 BROOKLYN met primary endpoint: LS mean LDL-C reduction 36.3% at day 84 (p<0.0001), sustained at day 365 (-41.5%); safety comparable to placebo.
July 29, 2024, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

NAMS: Phase 3 BROOKLYN trial of obicetrapib meets primary endpoint; LDL-C down 36.3% at day 84

LDL-C reduced 36.3% vs placebo at day 84 and 41.5% at day 365, both p<0.0001.
June 11, 2024, 7:59 PM ET other material materiality 0.65 positive item 7.01 item 8.01 item 9.01

NewAmsterdam Pharma obtains composition of matter patent for obicetrapib extending IP to July 2043

USPTO issued patent 12,006,305 covering amorphous obicetrapib hemicalcium, the product form for potential commercialization.
May 9, 2024, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01 ◈ Earnings Releases

NewAmsterdam Pharma Q1 net loss $93.8M; Phase 3 readouts on track for 2024

Enrolled over 9,500 patients in Phase 3 PREVAIL CVOT; topline data from BROOKLYN in Q3 2024 and BROADWAY in Q4 2024.
February 28, 2024, 6:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01 ◈ Earnings Releases

NewAmsterdam Pharma FY2023 net loss $176.9M; cash $340.5M; expects Phase 3 readouts in 2024

FY2023 net loss of $176.9M ($2.15 per share) vs $11.5M loss prior year; revenue fell to $14.1M from $102.7M.
February 15, 2024, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 7.01 item 8.01 item 9.01 ◈ Material Agreements

NewAmsterdam Pharma prices $175.3M public offering of shares and pre-funded warrants

Priced 4,488,159 ordinary shares at $19.00/share and 4,736,841 pre-funded warrants at $18.9999 each.
January 8, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

NewAmsterdam appoints William H. Lewis as Chair of Board, succeeds founder Sander Slootweg

William H. Lewis, CEO of Insmed since 2012, appointed Chair of NewAmsterdam's Board effective Jan 4, 2024.
January 4, 2024, 6:59 PM ET other material materiality 0.60 neutral item 7.01 item 9.01

NewAmsterdam Pharma announces 2024 strategic priorities; Phase 3 readouts in 3Q/4Q 2024

Expects topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024.